Entropy-driven catalysis-based lateral flow assay for sensitive detection of Alzheimer 's-associated MicroRNA

Talanta. 2024 May 1:271:125656. doi: 10.1016/j.talanta.2024.125656. Epub 2024 Jan 11.

Abstract

Alzheimer's disease (AD) is a degenerative disease of the brain worldwide. Currently, there is no effective cure. But accurate and early diagnosis of AD is critical to the development of patient care and future treatments. MiRNA-16 has been considered as an effective diagnostic biomarker for AD because of its regulatory effect on key proteins of AD. Herein, a colorimetric lateral flow assay (LFA) was developed for sensitive detection of miRNA-16 based on entropy-driven catalysis (EDC) amplification strategy. MiRNA-16 triggered EDC and released more linker DNAs (LDNA) of sandwich structure. Thus, AuNPs were enriched at the T-line to enhance the colorimetric signal and improve the sensitivity of visual assay. It showed good specificity and sensitivity for detecting miRNA-16 with a detection limit of 1.01 pM. The practical detection of miRNA-16 in human serum obtained satisfactory result. Significantly, EDC achieved signal amplification in homogeneous solution without enzyme and DNA labeling, leading to a cheap and easy detection of miRNA-16. Therefore, it provided a portable and rapid assay for AD-related nucleic acid, which holds a potential for point-of-care testing (POCT) of AD.

Keywords: Alzheimer's disease; Entropy-driven catalysis; Lateral flow assay; MiRNA-16.

MeSH terms

  • Alzheimer Disease* / diagnosis
  • Alzheimer Disease* / genetics
  • Biosensing Techniques*
  • Catalysis
  • DNA / chemistry
  • Entropy
  • Gold / chemistry
  • Humans
  • Limit of Detection
  • Metal Nanoparticles* / chemistry
  • MicroRNAs*
  • Nucleic Acid Amplification Techniques

Substances

  • MicroRNAs
  • Gold
  • DNA
  • MIRN16 microRNA, human